Company Overview: GenSpera

Industry News

29 Oct

World-Renowned Neuro-Oncologist Santosh Kesari, MD, PhD Joins GenSpera’s Scientific Advisory Board

SAN ANTONIO–(BUSINESS WIRE)– GenSpera, Inc. (OTC/QB: GNSZ), a San Antonio-based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announces that Santosh Kesari, MD, PhD, a board-certified neurologist and neuro-oncologist and a recognized leader in these fields, has joined the company’s Scientific Advisory Board. Dr. Kesari...

Read more

14 Oct

GenSpera to Present at the BIO Investor Forum

SAN ANTONIO–(BUSINESS WIRE)– GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage oncology drug discovery company developing a naturally occurring toxin in a targeted delivery system for solid tumors, announces that President and CEO Craig Dionne, Ph.D., is scheduled to present a corporate overview at the 14th Annual BIO Investor Forum on October...

Read more

9 Sep

GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors

SAN ANTONIO, TX–(Marketwired – Sep 9, 2015) –  GenSpera, Inc. (OTCQB: GNSZ) today announced that interim data from its Phase II study of mipsagargin (G-202) in adult patients with recurrent or progressive glioblastoma has demonstrated impressive activity in patients to date. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni,...

Read more

10 Aug

GenSpera Provides 2nd Quarter Corporate Update

SAN ANTONIO, TX–(Marketwired – Aug 10, 2015) – GenSpera, Inc. (OTCQB: GNSZ) on August 6, 2015, the company reported its financial results for the three and six months ended June 31, 2015, and has provided the following corporate update to its shareholders in order to highlight the Company’s extensive organizational advances and...

Read more

30 Jul

GenSpera Inc. – “Why Partner: The Partnering Process – Part Two”

GenSpera Inc. (GNSZ) today published a new blog post on The Chairman’s Blog, written by the Company’s chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. In the...

Read more

28 Jul

GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting

GenSpera, Inc. (OTCQB: GNSZ) announced today that the Society for Neuro-Oncology and the 2015 Scientific Program Committee has accepted an abstract for presentation at the Society for Neuro-Oncology’s 20th Annual Scientific Meeting. The abstract is titled: “Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelium, in...

Read more

20 Jul

U.S. Court of Appeals Enters Judgment in Favor of GenSpera

GenSpera, Inc.(OTCQB: GNSZ) announced today the U.S. Court of Appeals for the Federal Circuit found in favor of GenSpera. On July 16, 2015, the U.S. Court of Appeals for the Federal Circuit entered judgment in GenSpera, Inc. v. Annastasiah Mudiwa Mhaka in favor of GenSpera. In a per curiam...

Read more

14 Jul

GenSpera Inc. – “Expanded Intellectual Property for Thapsigargin Production”

GenSpera Inc.(GNSZ) today published a new blog post on The Chairman’s Blog, written by the Company’s chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. Dr. Dionne reflects...

Read more

13 Jul

Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)

Production of Thapsigargins by Thapsia Cell Suspension Culture” Filed by Phyton Biotech. GenSpera, Inc. (OTCQB: GNSZ) today announced that its strategic partner Phyton Biotech, the pioneer in Plant Cell Fermentation (PCF®), has had its international patent application WO 2015/0892978 A1 “PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE,” published by the World...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address